Hsp fusion protein with anti-chemorepellant agent for treatment of cancer
AssigneeThe General Hospital Corporation
InventorsMark C. Poznansky, Jeffrey A. Gelfand
Life of this patent
Estimating the term…
Abstract
This disclosure is directed to immune treatment of a disease (e.g., cancer) using a fusion protein in combination with an anti-chemorepellant agent. In particular, the fusion protein comprises an antigen-binding domain (e.g., an antibody or antibody fragment) and a stress protein domain
Claims43
A method for treating a cancer in a patient in need thereof, wherein said cancer expresses chemorepellant properties, the method comprising administering to the patient
- a) an effective amount of a fusion protein which fusion protein comprises a cancer cell binding component and a stress protein component, wherein said cancer cell binding component binds to the cancer cell and said stress protein component activates dendritic cells, leading to the generation of CD3 positive T-cells that target cancer antigens;
- and
- b) concurrently administering to said patient an effective amount of an anti-chemorepellant agent;
- wherein the combination of the fusion protein and the anti-chemorepellant agent treat the cancer.
A pharmaceutical composition comprising a fusion protein and an anti-chemorepellant agent, said fusion protein comprising a cancer cell binding:
- component and a stress protein component.
A kit of parts for treatment of a cancer in a patient, the kit comprising a therapeutically effective amount of an anti-chemorepellant agent and a fusion protein comprising a cancer cell binding component and a stress protein component, wherein the cancer cell binding component recognizes an antigen expressed by the cancer.
Dependencies are inferred from the claim text.